



## HOW TO GET HERE:



1200 W. Godfrey Ave.  
Philadelphia, PA 19141

### *Directions:*

We're located in the West Oak Lane section of Philadelphia, just off the 6200 block of Broad St, about 7 blocks north of Einstein Hospital. We're also only 3 blocks from the Fern Rock Transportation Center, the last stop on the Broad Street Subway Line.

There is ample free parking at The Eye Institute.

### *Map of The Eye Institute in West Oak Lane*



## What is the CITT: Attention and Reading Trial?

The CITT-ART was designed to find out whether therapy for CI improves reading and attention. Children with CI have many more symptoms when reading and show worse attention than children without CI.

We know that CI therapy improves these symptoms and we have some early evidence that treatment also results in improvements in reading and attention. However, to know for sure we need to study this question in a larger group of children and some children need to receive a harmless control therapy that is not designed to treat convergence insufficiency.

This study is being conducted at 8 sites across the United States and is funded by the National Eye Institute, which is a part of the National Institutes of Health. About 324 children will take part in the study.

For more information about the study, please go to

[WWW.CITT-ART.com](http://WWW.CITT-ART.com)

# CITT-ART

Convergence Insufficiency  
Attention & Reading Trial



## Information for Parents



## What is convergence insufficiency (CI)?

Convergence insufficiency (CI) affects about 5 out of every 100 people. CI is an eye-teaming problem in which the eyes have a strong tendency to drift outward when reading or doing work up close. If the eyes drift out, the person may see double. To avoid seeing double, a person with CI must use extra effort to make the eyes turn back in. This extra effort can lead to annoying symptoms that can interfere with the ability to read and work comfortably up close.

## What symptoms are often associated with convergence insufficiency?

- eyestrain and headaches during reading
- inability to concentrate when reading
- short attention span with reading and homework
- frequent loss of place
- blur during reading
- trouble remembering what was read
- the need to re-read the same line of words

## What treatment will my child receive?

If you agree to have your child take part in the study, a computer program will determine whether your child will receive active or control therapy. 2 of every 3 children will receive the active therapy. All children whose symptoms don't improve will be given the most effective treatment at no cost after the study period has ended.

## Are there risks?

The study involves standard tests and treatments which have the same risks as receiving treatment outside the study. No long-term problems are expected. The only known risk is that your child may continue to have eyestrain/headaches.



## Why should I volunteer my child to take part?

The best reason to volunteer for the CITT-ART is to be part of a national study designed to provide answers about how treatment of CI affects reading and attention. You will receive a summary of the reading test results. Your child will also receive treatment for CI at no cost, and you will be paid for all study visits.

## What do I need to do to allow my child take part?

If you agree to allow your child to take part in the study, you must be willing to bring your child to The Eye Institute at PCO for:

- 1) Initial testing to see if your child is eligible.
- 2) Initial tests of reading and attention.
- 3) Weekly therapy sessions for 16 weeks in a row.
- 4) Follow-up visits to check your child's vision, attention, and reading about one week and one year after completing the therapy.

You will need to ensure that your child performs the prescribed home therapy.

**Whom should I contact if I have questions or if I would like my child to take part?  
Karen Pollack, Study Coordinator, [kpollack@salus.edu](mailto:kpollack@salus.edu), 215-265-6053**

